Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1-beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants

Pediatric Infectious Disease Journal

Volumn 17, Issue 4, 1998, Pages 321-328

  Patterson, Angela M ^a   Taciak, Vicki ^a   Lovchik, Judith ^a   Fox, Renee E ^a   Campbell, Andrew B ^a   Viscardi, Rose M ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

Bronchopulmonary dysplasia; Interleukin 1 beta; Interleukin 6; Preterm; Tumor necrosis factor alpha; Ureaplasma urealyticum

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ASPIRATION BIOPSY; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; CYTOKINE RELEASE; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; TRACHEA MUCUS; UREAPLASMA UREALYTICUM;

BRONCHOPULMONARY DYSPLASIA; CYTOKINES; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTERLEUKIN-1; INTERLEUKIN-6; INTUBATION, INTRATRACHEAL; NASOPHARYNX; PROSPECTIVE STUDIES; TRACHEA; TUMOR NECROSIS FACTOR-ALPHA; UREAPLASMA UREALYTICUM;

EID: 0031970058     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199804000-00011     Document Type: Article

References (56)

1. O'Brodovich HM, Mellins RB. Bronchopulmonary dysplasia: unresolved neonatal acute lung injury. Am Rev Respir Dis 1985;132:694-709.
2. Coalson JJ, Kuehl TJ, Prihoda TJ, deLemos RA. Diffuse alveolar damage in the evolution of bronchopulmonary dysplasia in the baboon. Pediatr Res 1988;24:357-66.
3. Stenmark KR, Eyzaguirre M, Westcott JY, Henson PM, Murphy RC. Potential role of eicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia. Am Rev Respir Dis 1987;136:770-2.
4. Speer CP, Ruess D, Harms K, Herting E, Gefeller O. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993;91: 794-9.
5. Groneck P, Reuss D, Gotze-Speer B, Speer CP. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J Pediatr 1993;122:938-44.
6. Yoder MC, Chua R, Tepper R. Effect of dexamethasone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am Rev Respir Dis 1991;143:1044-8.
7. Merritt TA, Cochrane CG, Hallman M, et al. Reduction of lung injury by human surfactant treatment in respiratory distress syndrome. Chest 1983; 3:27S-30S.
8. Rosenfeld W, Concepcion L, Evans H, Jhaveri R, Sahdev S, Zabaleta I. Serial trypsin inhibitory capacity and ceruloplasmin levels in prematures at risk for bronchopulmonary dysplasia. Am Rev Respir Dis 1986;134:1229-32.
9. Groneck P, Gotze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics 1994;93:712-18.
10. Watts CL, Fanaroff AA, Bruce MC. Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J Pediatr 1992;120:614-20.
11. Kotecha S, Wangoo A, Silverman M, Shaw RJ. Increase in the concentration of transforming growth factor beta-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. J Pediatr 1996;128:464-9.
12. Rindfleisch MS, Hasday JD, Taciak V, Broderick K, Viscardi RM. Potential role of interleukin-1 in the development of bronchopulmonary dysplasia. J Interferon Cytokine Res 1996;16:365-73.
13. Viscardi RM, Hasday JD, Gumpper KF, Taciak V, Campbell AB, Palmer TW. Cromolyn sodium prophylaxis inhibits pulmonary proinflammatory cytokines in infants at high risk for bronchopulmonary dysplasia. Am J Respir Crit Care Med 1997;156:1523-9.
14. Bagchi A, Viscardi RM, Taciak V, Ensor JE, McCrea KA, Hasday JD. Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res 1994;36:244-52.
15. Romero R, Sirtori M, Oyarun E, et al. Infection and labor: V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. Am J Obstet Gynecol 1989;161:817-24.
16. Romero R, Manogue KR, Mitchell MD, et al. Infection and labor: IV. Cachectin-tumor necrosis factor in the amniotic fluid of women with intraamniotic infection and preterm labor. Am J Obstet Gynecol 1989;161:336-41.
17. Romero R, Avial C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in preterm labor. J Clin Invest 1990;85:1392-400.
18. Gibbs RS, Romero R, Hillier SL, Esechenbach DA, Sweet RL. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992;166:1515-28.
19. Hillier SL, Witkin SS, Krohn MA, Watts DH, Kiviat NB, Eschenbach DA. The relationship of amniotic fluid cytokines and preterm delivery, amniotic fluid infection, histologic chorioamnionitis, and chorioamnion infection. Obstet Gynecol 1993;81:941-8.
20. Groneck P, Goetze-Speer B, Speer CP. Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth. Arch Dis Child Fetal Neonatal Ed 1996;74:F51-5.
21. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996;97: 210-15.
22. Grattard F, Soleihac B, De Barbeyrac B, Bebear C, Seffert P, Pozzetto B. Epidemiologic and molecular investigations of genital mycoplasmas from women and neonates at delivery. Pediatr Infect Dis J 1995;14:853-8.
23. Sanchez PJ. Perinatal transmission of Ureaplasma urealyticum: current concepts based on review of the literature. Clin Infect Dis 1993;17(Suppl 1):S107-11.
24. Alfa MJ, Embree JE, Degagne P, et al. Transmission of Ureaplasma urealyticum from mothers to full and preterm infants. Pediatr Infect Dis J 1995;14:341-5.
25. Wang EL, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995;127:640-4.
26. Iles R, Lyon A, Ross P, McIntosh N. Infection with Ureaplasma urealyticum and Mycoplasma hominis and the development of chronic lung disease in preterm infants. Acta Paediatr 1996;85:482-4.
27. Pacifico L, Panero A, Roggini M, Rossi N, Bucci G, Chiesa C. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997;16: 579-86.
28. Da Silva O, Gregson, D, Hammerberg O. Role of Ureaplasma urealyticum and Chlamydia trachomatis in development of bronchopulmonary dysplasia in very low birth weight infants. Pediatr Infect Dis J 1997;16:364-9.
29. van Waarde WM, Brus F, Okken A, Kimpen JL. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 1997;10:886-90.
30. Waites KB, Crouse DT, Cassell GH. Systemic neonatal infection due to Ureaplasma urealyticum. Clin Infect Dis 1993; 17(Suppl 1):S131-5.
31. Crouse DT, Odrezin GT, Cutter GR, et al. Radiographic changes associated with tracheal isolation of Ureaplasma urealyticum from neonates. Clin Infect Dis 1993;17(Suppl 1):S122-30.
32. Panero A, Pacifico L, Roggini M, Chiesa C. Ureaplasma urealyticum as a cause of pneumonia in preterm infants: analysis of the white cell response. Arch Dis Child 1995;73: F37-40.
33. Ohlsson A, Wang E, Vearncombe M. Leukocyte counts and colonization with Ureaplasma urealyticum in preterm neonates. Clin Infect Dis 1993;17(Suppl 1):S144-7.
34. Walsh WF, Butler J, Coalson J, Hensley D, Cassell GH, deLemos RA. A primate model of Ureaplasma urealyticum infection in the premature infant with hyaline membrane disease. Clin Infect Dis 1993;17(Suppl 1):S158-62.
35. Rudd PT, Cassell GH, Waites KB, Davis JK, Duffy LB. Ureaplasma urealyticum pneumonia: experimental production and demonstration of age-related susceptibility. Infect Immun 1989;57:918-25.
36. De Silva NS, Quinn PA. Endogenous activity of phospholipases A and C in Ureaplasma urealyticum. J Clin Microbiol 1986;23:354-9.
37. Baldie G, Kaimakamis D, Rotondo D. Fatty acid modulation of cytokine release from human monocytic cells. Biochim Biophys Acta 1993;1179:125-33.
38. Rola-Pleszczynski M, Thivierge M, Gagnon N, Lacasse C, Stankova J. Differential regulation of cytokine and cytokine receptor genes by PAF, LTB4 and PGE2. J Lipid Med 1993;6:175-81.
39. Holladay CS, Wright RM, Spangelo BL. Arachidonic acid stimulates interleukin-6 release from rat peritoneal macrophages in vitro: evidence for a prostacyclin-dependent mechanism. Prostaglandins Leukot Essent Fatty Acids 1993;49: 915-22.
40. Viscardi RM, Broderick K, Sun CCJ, et al. Disordered pathways of fibrin turnover in lung lavage of premature infants with respiratory distress syndrome. Am Rev Respir Dis 1992;146:492-9.
41. Shepard MC. Culture media for ureaplasmas. In: Razin S, Tully JG, eds. Methods in mycoplasmology. vol. 1. New York: Academic, 1983:137-46.
42. Toce SS, Farrell PM, Leavitt LA, Samuels DP, Edwards DK. Clinical and roentgenographic scoring systems for assessing bronchopulmonary dysplasia. Am J Dis Child 1984;138: 581-5.
43. Berberich MA, Group NW. Assessment of lung function and dysfunction in studies of infants and children. Am Rev Respir Dis 1993;148:1105-8.
44. Dinarello CA, Wolff SM. The role of interleukin-1 in disease. N Engl J Med 1993;328:106-13.
45. 2 by human neutrophils. Scand J Rheumatol (Suppl) 1988;76:318-24.
46. Ulich TR, Yin S, Guo K, Yi ES, Remick D, del Castillo J. Intratracheal injection of endotoxin and cytokines: II. Interleukin-6 and transforming growth factor beta inhibit acute inflammation. Am J Pathol 1991;138:1097-101.
47. Shanley TP, Foreback JL, Remick DG, Ulich TR, Kunkel SL, Ward PA. Regulatory effects of interleukin-6 in immunoglobulin G immune-complex-induced lung injury. Am J Pathol 1997;151:193-203.
48. Ulich TR, Yin S, Guo K, del Castillo J, Eisenberg SP, Thompson RC. The intratracheal administration of endotoxin and cytokines: III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin-and IL-1-induced acute inflammation. Am J Pathol 1991;138:521-4.
49. Barton BE, Jackson JV. Protective role of interleukin-6 in the lipopolysaccharide-galactosamine septic shock model. Infect Immun 1993;61:1496-9.
50. Aderka D, Le J, Vilcek J. IL-6 inhibits lipopolysaccharide-induced tumor necrosis factor production in cultured human monocytes, U937 cells, and in mice. J Immunol 1989;143: 3517-23.
51. van der Poll T, Keogh CV, Guirao X, Buurman WA, Kopf M, Lowry SF. Interleukin-6 gene-deficient mice show impaired defense against pneumococcal pneumonia. J Infect Dis 1997; 176:439-44.
52. Schibler KR, Liechty KW, White WL, Rothstein G, Christensen RD. Defective production of interleukin-6 by monocytes: a possible mechanism underlying several host defense deficiencies of neonates. Pediatr Res 1992;31:18-21.
53. Yachie A, Takano N, Ohta K, et al. Defective production of interleukin-6 in very small premature infants in response to bacterial pathogens. Infect Immun 1992;60:749-53.
54. Romero R, Tartakovsky B. The natural interleukin-1 receptor antagonist prevents interleukin-1-induced preterm delivery in mice. Am J Obstet Gynecol 1992;167:1041-5.
55. Grigg JM, Barber A, Silverman M. Increased levels of bronchoalveolar lavage fluid interleukin-6 in preterm ventilated infants after prolonged rupture of membranes. Am Rev Respir Dis 1992;145:782-6.
56. Cassell GH, Waites KB, Crouse DT, et al. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet 1988;2:240-4.